8-K: Upexi Sells VitaMedica Subsidiary for $6 Million

Upexi, Inc. has completed the sale of its wholly-owned subsidiary, VitaMedica, Inc., for a total consideration of $6 million.

Summary

• Upexi, Inc. sold 100% of its subsidiary, VitaMedica, Inc., to a buyer group on June 13, 2024.
• The total purchase price was $6 million.
• $4 million was paid in cash at closing.
• $1 million is in the form of promissory notes due in one year.
• The remaining $1 million is payable in 15 months, subject to a working capital adjustment.
• The buyer group includes Nutra Products LLC, MFA Holdings Corp., and 1 Ontario Inc.
• MFA Holdings Corp. is controlled by Upexi's CEO and Chairman, Allan Marshall.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The sale provides cash and future payments, but the related party aspect and the use of promissory notes introduce some uncertainty.

Positives

• Upexi received $4 million in cash immediately from the sale.
• The sale provides Upexi with an additional $2 million in future payments.
• The transaction allows Upexi to divest a subsidiary and potentially focus on other areas of its business.

Negatives

• The sale includes $1 million in promissory notes, which are subject to payment risk.
• The final $1 million payment is subject to a working capital adjustment, which could reduce the amount received.
• The sale involves a related party transaction with the CEO's controlled entity.

Risks

• There is a risk that the promissory notes may not be paid in full.
• The final $1 million payment is subject to a working capital adjustment, which could reduce the amount received.
• The related party transaction with the CEO's controlled entity could raise conflict of interest concerns.

Future Outlook

The document does not contain specific forward-looking statements or guidance beyond the terms of the sale agreement.

Management Comments

• The document does not contain direct quotes from management.
• The transaction was authorized by the board of directors.

Industry Context

The sale of a subsidiary is a common corporate strategy to streamline operations or raise capital. The involvement of the CEO in the buyer group is a notable aspect of this transaction.

Comparison to Industry Standards

• The sale of a subsidiary for a mix of cash and promissory notes is a fairly standard transaction structure.
• The valuation of $6 million for VitaMedica would need to be compared to similar companies in the nutraceutical or health supplement industry to assess if it is a fair price.
• Comparable transactions would include the sale of similar sized health and wellness companies, but without more information on VitaMedica's financials, a direct comparison is difficult.

Related Party Transactions

• The buyer group includes MFA Holdings Corp., which is controlled by Upexi's CEO and Chairman, Allan Marshall.

Stakeholder Impact

• Shareholders may view the sale positively as it provides cash and reduces the company's operational complexity.
• Employees of VitaMedica will transition to new ownership.
• Customers and suppliers of VitaMedica will likely experience a change in ownership.

Next Steps

• Upexi will receive the $1 million promissory note payment in one year.
• Upexi will receive the final $1 million payment in 15 months, subject to working capital adjustments.

Key Dates

Keywords

acquisition, sale, subsidiary, VitaMedica, Upexi, divestiture, promissory notes, working capital, related party transaction